Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2025-03-28 00:00:00 ET · period of report 2025-03-28 · accession 0001867096-25-000058 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-28 | 2025-03-28 | XERS | Brady James Aloysius | Dir | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-28 | A | A | 100,000 | $0.00 | 100,000 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. |